Rotavirus VP6 |
|
Vaxjo ID |
400 |
|
Vaccine Adjuvant Name |
Rotavirus VP6 |
|
Alternative Names |
VP6 or RV VP6 |
|
Adjuvant VO ID |
VO_0005682
|
|
Description |
VP6 is the most abundant protein in the rotavirus structure, forming the intermediate layer of the virion and is highly immunogenic. It is known to induce immune responses that can protect against rotavirus infections. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Structure |
VP6 forms oligomeric structures, including nanotubes and nanospheres, depending on conditions such as pH and ionic strength. |
|
Storage |
VP6 is stored at +4°C until use. |
|
Preparation |
VP6 was produced in Nicotiana benthamiana plants using a magnICON(R) vector system and purified using chromatography techniques. |
|
Dosage |
In the study, VP6 was administered at a dose of 10 ug when combined with suboptimal doses of Norovirus VLPs. |
|
Function |
Rotaviruses (RVs) and noroviruses (NoVs) are major causes of childhood acute gastroenteritis. During development of a combination vaccine based on NoV virus-like particles (VLP) and RV VP6 produced in baculovirus expression system in insect cells, a dual role of VP6 as a vaccine antigen and an adjuvant for NoV-specific immune responses was discovered. |
|
Safety |
The article indicates that VP6 is considered safe as it has been shown to stimulate immune responses without adverse effects in the studied models. |
| References |
Malm et al., 2019: Malm M, Diessner A, Tamminen K, Liebscher M, Vesikari T, Blazevic V. Rotavirus VP6 as an Adjuvant for Bivalent Norovirus Vaccine Produced in Nicotiana benthamiana. Pharmaceutics. 2019; 11(5); . [PubMed: 31083495].
|
